Every material Form 8-K GeneDx Holdings Corp. has filed with the SEC since May 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
GeneDx reported third quarter 2026 revenue of $123.1 million, up 5% year-over-year, and exome and genome volume growth of 25%. The company reiterated its full-year 2026 revenue guidance of $475 to $490 million, but the guidance table shows lower growth targets for exome and genome volume and revenue than the previous guidance. Adjusted net income fell from $16.1 million a year earlier, and the GAAP net loss widened to $12.3 million.
Q3 2026 revenue $123.1 million, up 5% year-over-year; exome and genome revenue $110.4 million, up 12%
Adjusted net income $8.6 million versus $16.1 million in Q3 2025; GAAP net loss $12.3 million versus $7.6 million a year earlier
Full-year 2026 exome and genome volume growth target listed as at least 28%, versus at least 30% previously; exome and genome revenue growth target at least 17%, versus at least 20% previously
GeneDx reported second quarter 2026 revenue of $114.4 million, up 11% year-over-year, with exome and genome volume up 32%. It posted a GAAP net loss of $17.7 million, compared with net income of $10.8 million a year earlier, and reaffirmed full-year 2026 revenue guidance of $475 to $490 million, while its loan facility with Blackstone was expanded to $150.0 million.
Q2 2026 revenue was $114.4 million, up 11% year-over-year; exome and genome test volume was 30,785, up 32%.
GAAP net loss was $17.7 million ($0.60 per share) versus net income of $10.8 million in Q2 2025; adjusted net income was $0.4 million versus $16.4 million a year earlier.
Full-year 2026 revenue guidance of $475 to $490 million was reaffirmed; third-quarter revenue guidance is $122 to $124 million.
On August 3, 2026, the Blackstone loan facility was increased to $150.0 million, and pro forma cash is approximately $188 million.
GeneDx Holdings named Mark Gardner, 60, as President effective June 15, 2026, to oversee its lab and commercial operations. He reports to CEO Katherine Stueland and joins the executive leadership team after serving as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics from September 2022 to June 2026. The filing also says Bryan Dechairo will move into a role leading product, technology and innovation initiatives.
Mark Gardner, 60, effective June 15, 2026; reports to CEO Katherine Stueland
Employment terms: base salary of $530,000, target annual bonus of 65% of base salary, and restricted stock units with a $2,000,000 grant-date value vesting over four years
Severance without cause or for good reason: 9 months of base salary continuation and 12 months of health coverage; enhanced terms apply within 12 months after a change in control
Bryan Dechairo will transition to leading product, technology and innovation initiatives
GeneDx reported first-quarter 2026 revenue of $102.3 million, up 17% year over year, but lowered its full-year 2026 revenue guidance to $475 million to $490 million from $540 million to $555 million. The company also reported a GAAP net loss of $63.3 million, including a $31.3 million impairment loss, which matters to shareholders because the revenue outlook has been reset and the quarter swung from a year-earlier adjusted profit to an adjusted loss.
Q1 2026 revenue was $102.3 million, up 17% from $87.1 million a year earlier; exome and genome test revenue rose 27% to $90.6 million.
Full-year 2026 revenue guidance was updated to $475 million to $490 million, down from the previous $540 million to $555 million.
GAAP net loss was $63.3 million, or $2.16 per share, including a $31.3 million impairment loss; adjusted net loss was $8.2 million versus adjusted net income of $9.2 million in Q1 2025.
Cash, cash equivalents, marketable securities and restricted cash totaled $171.7 million as of March 31, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every GeneDx Holdings Corp. filing is on SEC EDGAR ↗. 8-K briefs of other companies →